An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction
An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction作者机构：Department of Urology Peking Union Medical College Hospital Beijing 100730 China Department of Urology Peking University People's Hospital Beijing 100044 China Department of Andrology Nanjing Drum Tower Hospital Jiangsu 210008 China Department of Medical Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai 200021 China
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2016年第18卷第5期
页 面：773-779页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 02[经济学] 0201[经济学-理论经济学] 020105[经济学-世界经济] 10[医学]
主 题：erectile dysfunction partners' preference sexual quality of life sildenafil tadalafil
摘 要：The impact of erectile dysfunction is distressing to both males and their female partners, but less attention has been paid to identify female partners＇ preferred treatment and sexual quality of life outcomes. The present analysis explores female partners＇ treatment preference for erectile dysfunction in Chinese Men. This was a phase 4, randomized, open-label, multicenter, crossover study in Chinese men with erectile dysfunction who were na＇fve to phosphodiesterase type 5 inhibitor treatments. Eligible patients were randomized to sequential 20-mg tadalafil/100-mg sildenafil or lO0-mg sildenafil/20-mg tadalafil for 8 weeks each. Of 418 patients, female partners of 64 patients agreed to enter the study; of 64 patients who entered the study with female partners, 63 were randomized, and 62 completed the study. Baseline demographics and disease characteristics were comparable between treatment groups. Significantly more couples preferred tadalafil compared with sildenafil overall （75.4% vs 24.6%; P〈 0.001）, and irrespective of erectile dysfunction severity at baseline （P 〈 0.005）. Significant improvements in sexual quality of life scores were reported at endpoint （Visit 8） in male patients and female partners in both tadalafil and sildenafil treatment groups （P 〈 0.001）. Significantly higher mean changes from baseline were observed for male patients in the tadalafil group compared with the sildenafil group for the erectile function （P = 0.013） and overall satisfaction （P = 0.019） International Index for Erectile Function domains and the spontaneity domain （P〈 0.001） of the Psychological and Interpersonal Relationship Scale. No major safety concerns were reported during the study. Though both treatments were effective, safe, and tolerable, more couples preferred tadalafil compared with sildenafil.
维普期刊数据库